HIF1A and ovarian cancer: Furthermore using the experimental models to test the efficacy of rapamycin in ovarian cancer treatment, a significant correlation between HIF-1α inhibition and VEGF down-regulation or increase of apoptosis has been demonstrated [31], and it was mentioned that rapamycin delays the tumour onset and progression [32].